NEW YORK, Oct. 9 – Sequitur has entered into an agreement with Procter and Gamble Pharmaceuticals to provide the company access to its functional genomics technology, the companies announced Tuesday.
Sequitur, based in Natick, Mass., will perform biological screening and supply its proprietary antisense compounds and methods to Procter and Gamble for use in its target validation studies as part of a multi-year agreement, according to the companies.
Financial details were not disclosed.
“We are pleased to enter into this collaboration with Sequitur, which promises to accelerate the validation of our genomic targets across our therapeutic areas,” Gordon Hassing, vice president of R&D at Procter and Gamble Pharmaceuticals, said in a statement.
In September, Sequitur signed a multi-year agreement with Minneapolis-based Discovery Genomics to collaborate on screening antisense compounds and studying gene function in zebra fish.